For the quarter ending 2025-09-30, SPRO had $17,422K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,382 | -15,566 |
| Depreciation and amortization | 0 | 0 |
| Non-cash lease cost | 283 | 551 |
| Impairment charges | 587 | - |
| Share-based compensation | 1,048 | 2,270 |
| Collaboration receivable, current and non-current - related party | -23,585 | -24,938 |
| Other receivables | -869 | -625 |
| Prepaid expenses and other current assets | -47 | -616 |
| Other assets | 0 | 0 |
| Accounts payable | 615 | -6,526 |
| Accrued expenses and other current liabilities | 1,082 | -10,997 |
| Deferred revenue, current and non-current | 0 | -12 |
| Deferred revenue - related party, current and non-current | -3,048 | -16,901 |
| Other long-term liabilities | 0 | 0 |
| Operating lease liability | -264 | -682 |
| Income taxes | 0 | -11 |
| Net cash used in operating activities | 17,422 | -21,695 |
| Net decrease in cash and cash equivalents | 17,422 | -21,695 |
| Cash and cash equivalents at beginning of period | 52,889 | - |
| Cash and cash equivalents at end of period | 48,616 | - |
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)